Nuvectis Pharma Inc., a clinical stage biopharmaceutical company, has announced the initiation of the Phase 1b program for its investigational drug NXP900. The program aims to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors with specific genetic alterations and in combination with EGFR and ALK inhibitors in NSCLC patients who have developed resistance to these treatments. The announcement follows the successful completion of previous studies, including a dose escalation study in patients with advanced solid tumors and a clinical drug-drug interaction study in healthy volunteers. The company has scheduled a conference call for August 12, 2025, to discuss the details of the Phase 1b program and the market opportunity for NXP900. Results from this program are anticipated in the future, as the single agent component has just begun and the combination component is expected to start later this year.